Medical Incubator Japan K.K.
Venture capitalTokyo · Series A–Series B
Investment thesis
MIJ is a professional group specializing in healthcare investment. It invests in domestic and international startups developing first-in-class or best-in-class pharmaceuticals, spanning the latest technologies such as regenerative medicine and gene therapy through to small-molecule fields, as well as startups building devices and digital health services that bring innovation to the delivery of medical care. The firm combines global sourcing capabilities, evaluation expertise from healthcare business and investment professionals, and commercialization support intended to lead investments to success, aiming to bring hope to patients and returns to investors.
Source: firm website, verified Aug 3, 2026.
What they invest in
from 9 of 19 portfolio companiesHealthtech ×9Biotech ×8Medical Devices ×4Deep Tech ×3AI & Machine Learning ×1Digital Health ×1EdTech ×1
HQs:Japan×4United States×2United Kingdom×1
Investments · 19 tracked
founders shown can be your intro pathDermatology-focused R&D company using a proprietary nanoformulation technology to deliver drugs efficiently to hard-to-reach tissues like skin and nails.
Provides clinical information to physicians and healthcare professionals online and offers pharmaceutical companies effective drug-information delivery solutions (TSE Prime 2105).
Developing gene therapy adipocyte drugs carrying therapeutic protein genes for congenital enzyme/protein deficiency diseases.
Developing a pan-γδT cell engager that activates multiple γδT cell subsets to target antigens beyond the reach of conventional T cell engagers.
Cytospire Therapeutics develops multispecific antibodies and next-generation γδ T cell engagers designed to direct innate and adaptive immune effector cells as an alternative to CD3-based engagers.
BiotechHealthtech
Co-investorsCriteria Bio VenturesLifeArc VenturesModi VenturesPathway BioventuresSound Bioventures
DiscGenics develops an allogeneic, injectable disc progenitor cell therapy (IDCT/rebonuputemcel) for painful lumbar degenerative disc disease, currently advancing toward a Phase III clinical program.
BiotechHealthtechMedical DevicesSalt Lake City, US
Flagg Flanagan(CEO & Chairman)Bob Wynalek(COO & Board Member)
Heartseed develops cardiac regenerative medicine, creating heart muscle cells from iPS cells for transplantation to treat heart failure, with its lead pipeline HS-001 nearing clinical trials.
BiotechHealthtechMedical Devices
Keiichi Fukuda(代表取締役社長 (President & CEO))
Co-investorsAngel Bridge Co.,Ltd.Astellas Venture Management LLCKeio Innovation InitiativeSMBC Venture CapitalSumitomo Mitsui Trust nvestment Co. Ltd.UTokyo Innovation Platform Co. Ltd.
Co-investorsEIR Ventures
IgGenix is a clinical-stage biotechnology company focused on antibody discovery and development for allergies and immunological diseases.
AI & Machine LearningBiotechHealthtechSouth San Francisco, US
Kari Nadeau(Scientific Co-Founder)
Co-investorsKhosla VenturesAllerfund Ventures, LlcFemHealth VenturesGlobal BrainShangBay Capital LLCSBI Investment
ILC Therapeutics is a biotechnology company developing hybrid interferon therapeutics, including its Alfacyte product, based on an interferon platform.
BiotechDeep TechHealthtechMedical Devices
Owain Millington(CEO)
Co-investorsEos Advisory
Develops drugs against previously undruggable targets using its proprietary CRISPR-GNDM (Guide Nucleotide Directed Modulation) platform based on modified CRISPR-Cas9 genome editing.
Co-investorsFast Track Initiative
Biotech with a CRISPR-based therapeutic platform aiming to develop treatments for genetic diseases (TSE Growth 4883).
Develops, manufactures, and sells regenerative cell drugs for CNS disorders such as chronic stroke and traumatic brain injury (TSE Growth 4592).
Developing gene therapy adipocyte-based products carrying therapeutic protein genes to treat inherited diseases caused by enzyme or functional protein deficiencies.
CellGenTech develops ex-vivo gene therapy products using gene-transduced human adipose cells (GMAC) to treat rare diseases such as familial LCAT deficiency, Fabry disease, and hemophilia.
BiotechDeep TechHealthtechChiba, JP
麻生雅是(代表取締役社長 (President & CEO))
A gene therapy company developing treatments for neurodegenerative diseases, with a pipeline of more than ten programs led by candidates for ALS and Parkinson's disease.
BiotechHealthtechMedical Devices
Modalis Therapeutics develops therapeutics using CRISPR gene-editing technology and provides its platform technology for drug development.
BiotechDeep TechHealthtechTokyo, JP
Haruhiko Morita(代表取締役CEO (President & CEO))
Co-investorsNippon Venture CapitalShinsei Capital PartnersSMBC Venture CapitalUTokyo Innovation Platform Co. Ltd.
Frequently asked questions
- How many investments has Medical Incubator Japan K.K. made?
- Medical Incubator Japan K.K. has 19 tracked investments.
- What stage does Medical Incubator Japan K.K. invest at?
- Medical Incubator Japan K.K. invests at the Series A, Series B stages.
- What sectors does Medical Incubator Japan K.K. focus on?
- Medical Incubator Japan K.K. focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Medical Incubator Japan K.K. located?
- Medical Incubator Japan K.K. is headquartered in Tokyo, JP.
- Who does Medical Incubator Japan K.K. co-invest with?
- Medical Incubator Japan K.K. most often shares deals with SMBC Venture Capital, UTokyo Innovation Platform Co. Ltd., Allerfund Ventures, Llc, among 19 tracked co-investors.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.